• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    119.70 -1.14 (-0.94%)
    Streaming Delayed Price Updated: 12:23 PM EDT, Apr 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,697,194
    Open 120.37
    Bid (Size) 119.65 (100)
    Ask (Size) 119.71 (100)
    Prev. Close 120.84
    Today's Range 119.25 - 121.65
    52wk Range 73.31 - 125.14
    Shares Outstanding 2,531,374,696
    Dividend Yield 2.84%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
    From Merck & Co., Inc.
    Via Business Wire

    Performance

    YTD
    +12.4%
    +12.4%
    1 Month
    -1.4%
    -1.4%
    3 Month
    +13.7%
    +13.7%
    6 Month
    +32.8%
    +32.8%
    1 Year
    +37.4%
    +37.4%

    More News

    Read More
    News headline image
    The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
    Via Finterra
    Topics Artificial Intelligence Earnings Economy
    News headline image
    Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
    Via MarketMinute
    Topics Economy Intellectual Property Stocks
    News headline image
    Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
    Via Finterra
    Topics Initial Public Offering
    News headline image
    Merck Just Made a Big Bet on a New Cancer Growth Engine ↗
    Via MarketBeat
    News headline image
    Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    1 Reason Eli Lilly Stock Is Still a Buy ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗
    Via The Motley Fool
    News headline image
    MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
    Via MarketMinute
    Topics Intellectual Property
    ARM Makes Its Move While Wall Street Watches the Strait ↗
    Via Chartmill
    News headline image
    The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
    Via Finterra
    Topics Initial Public Offering Intellectual Property World Trade
    News headline image
    Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
    From Terns Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    1 S&P 500 Stock to Target This Week and 2 We Ignore
    Via StockStory
    Topics Stocks
    News headline image
    Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
    Via MarketMinute
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Pfizer vs Moderna: Which Pharma Stock Has More Upside? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    News headline image
    The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
    Via MarketMinute
    Topics Earnings Economy Initial Public Offering

    Frequently Asked Questions

    Is Merck & Co publicly traded?
    Yes, Merck & Co is publicly traded.
    What exchange does Merck & Co trade on?
    Merck & Co trades on the New York Stock Exchange
    What is the ticker symbol for Merck & Co?
    The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
    What is the current price of Merck & Co?
    The current price of Merck & Co is 119.70
    When was Merck & Co last traded?
    The last trade of Merck & Co was at 04/02/26 12:23 PM ET
    What is the market capitalization of Merck & Co?
    The market capitalization of Merck & Co is 303.01B
    How many shares of Merck & Co are outstanding?
    Merck & Co has 303B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.